Repatha (evolocumab) lowered the risk of death from any cause by 20% in high-risk adults without a previous heart attack or ...

The FDA has approved Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke in ...

Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says outreach and texting will be key to keeping eligible Medicaid enrollees covered under new redetermination and ...

University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict ...

The FDA has approved Lisraya (brepocitinib) to treat adults with dermatomyositis, rare autoimmune disease. Dermatomyositis ...

The FDA has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for pediatric patients weighing at least 2 kg, according to ...

A large multicenter trial testing intravenous arginine as a treatment for acute pain crises in sickle cell patients has ended ...

The FDA has approved Rasonque (daraxonrasib), a first-in-class targeted therapy for metastatic pancreatic cancer, more than ...

A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients ...

Tevimbra plus Ziihera with chemo raises survival in first-line HER2-positive gastroesophageal cancer, offering a new FDA-approved option.

The rationale for active surveillance is that follicular lymphoma is an indolent disease, Poh explains, and in asymptomatic ...

Follicular lymphoma accounts for between 20% and 30% of all non-Hodgkin lymphomas, so while relatively uncommon as a cancer, ...